Tonix Pharmaceuticals Announces Proposed Public Offering
June 26, 2024 16:40 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it...
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 26, 2024 15:13 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company, today announced that it has...
Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
June 25, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonix’s live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose TNX-801 vaccination demonstrated efficacy in protecting animals from lethal...
Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
June 20, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Company aligned with FDA on key CMC topics Tonix also has completed the second and final pre-New Drug Application (NDA) meeting and discussed nonclinical, clinical pharmacology and clinical matters...
Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)
June 18, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Gap in non-oral prescriptions relative to AHS guidelines represents an opportunity to increase awareness of Tonix’s two FDA-approved non-oral treatments for acute migraine Zembrace® SymTouch®...
Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024
June 17, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain and demonstrated broad fibromyalgia symptom improvement, as demonstrated...
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
June 13, 2024 17:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
June 12, 2024 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has...
Tonix Pharmaceuticals Announces Proposed Public Offering
June 11, 2024 17:17 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it...
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
June 06, 2024 11:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), fully-integrated biopharmaceutical company with marketed products and a...